News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGE...

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA®

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Heal...

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcar

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufact...

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demo...

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstra

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Out...

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro F...

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Footba

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in No...

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in Novembe

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as ...

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Tre

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5,
See all news items
Previous
Next

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more Discover the world of Teva

Media Resources

Media Inquiries

Contact our corporate communications.

Learn more Media Inquiries

Media Kit

Files and resources for media use only

Download Teva Media Kit Media Kit

Financial Reports

View Teva financial news on our global website.

Learn more Financial Reports

Connect with us

Teva Social Media Guidelines.

Learn more Connect with us